Q-omics provides the consensus-scored SNAP25-AS1 profile across patient tissues and cancer cell-line models. SNAP25-AS1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SNAP25-AS1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, SNAP25-AS1 RNA expression shows 14,189 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, THCA, and KIRP as cancer lineages where SNAP25-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNAP25-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNAP25-AS1 survival associations across molecular data types. SNAP25-AS1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNAP25-AS1 RNA expression–survival associations across cancer types. High SNAP25-AS1 expression shows unfavorable associations in BLCA, STAD, UVM and GBM, but favorable associations in LGG and ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SNAP25-AS1 RNA expression.
This table summarizes SNAP25-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNAP25-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNAP25-AS1 shows lower tumor expression in UCEC and higher tumor expression in THCA, KIRC, KIRP, HNSC and LIHC. The THCA box plot shows higher SNAP25-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.131, t-test p < 0.001).
This table shows molecular features associated with SNAP25-AS1 in patient tissues and cancer cell lines. In patient samples, SNAP25-AS1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
